Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun;15(6):9641-9646.
doi: 10.3892/ol.2018.8580. Epub 2018 Apr 26.

Cardamonin reduces chemotherapy resistance of colon cancer cells via the TSP50/NF-κB pathway in vitro

Sen Lu  1 , Caizhao Lin  1 , Xiaobin Cheng  1 , Hanju Hua  1 , Tao Xiang  1 , Yu Huang  1 , Xi Huang  1
Affiliations

Cardamonin reduces chemotherapy resistance of colon cancer cells via the TSP50/NF-κB pathway in vitro

Sen Lu et al. Oncol Lett. 2018 Jun.

Abstract

It has previously been reported that cardamonin is able to regulate glycometabolism and vasodilation whilst also exhibiting anti-inflammatory and antitumor properties. The antitumor effect of cardamonin is multifaceted, and so it is necessary to investigate the antitumor mechanisms of cardamonin at the molecular level. Cardamonin alters chemotherapy-resistant colon cancer cell growth; however, the underlying mechanism is unknown. The present study was conducted to investigate the effect of cardamonin on chemotherapy-resistant colon cancer cells and the possible mechanisms of action. Cardamonin significantly suppressed the growth of chemotherapy-resistant colon cancer cells, induced apoptosis and promoted caspase-3/9 activity and Bax protein expression in 5-fluorouracil (5-FU)-resistant HCT-116 cells. Cardamonin significantly suppressed c-MYC, octamer-binding transcription factor 4, cyclin E, testes-specific protease 50 and nuclear factor-κB protein expression in 5-FU-resistant HCT-116 cells. The findings of the present study demonstrate that cardamonin suppresses chemotherapy-colon cancer cell via the NF-κB pathway in vitro.

Keywords: cardamonin; chemotherapy-colon cancer cell; nuclear factor-κB.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Chemical structure of cardamonin.
Figure 2.
Figure 2.
Effect of cardamonin on chemotherapy-resistant colon cancer cell growth. **P<0.01 vs. DMSO control group. DMSO, dimethyl sulfoxide.
Figure 3.
Figure 3.
Effect of cardamonin on chemotherapy-resistant colon cancer apoptosis. Effect of cardamonin on chemotherapy-resistant colon cancer apoptosis rate using (A) statistical analysis, and (B) flow cytometer. **P<0.01 vs. DMSO control group. DMSO, dimethyl sulfoxide.
Figure 4.
Figure 4.
Effect of cardamonin on (A) caspase-3 and (B) caspase-9 activity in chemotherapy-resistant colon cancer cells. **P<0.01 vs. DMSO control group. DMSO, dimethyl sulfoxide.
Figure 5.
Figure 5.
(A) Western blotting and densitometry analysis of the effect of cardamonin on (B) Bax, (C) c-MYC and (D) Oct4 protein expression in 5-fluorouracil-resistant colon cancer cells. **P<0.01 vs. DMSO control group. Bax, Bcl-2-associated X protein; c-MYC, Myc proto-oncogene protein; Oct4, octamer-binding transcription factor 4; DMSO, dimethyl sulfoxide.
Figure 6.
Figure 6.
(A) Western blotting and densitometry analysis of the effect of cardamonin on (B) cyclin E, (C) TSP50 and (D) NF-κB protein expression in 5-fluorouracil-resistant colon cancer cells. **P<0.01 vs. DMSO control group. TSP50, testes-specific protease 50; NF-κB, nuclear factor-κB; DMSO, dimethyl sulfoxide.
Figure 7.
Figure 7.
Cardamonin suppresses chemotherapy-resistance in colon cancer cells via the TSP50/NF-κB pathway in vitro. TSP50, testes-specific protease 50; NF-κB, nuclear factor-κB; Bax, Bcl-2-associated X protein; c-MYC, Myc proto-oncogene protein.
See this image and copyright information in PMC

References

    1. Kobayashi T, Masaki T, Kogawa K, Matsuoka H, Sugiyama M. Efficacy of gum chewing on bowel movement after open colectomy for left-sided colorectal cancer: A randomized clinical trial. Dis Colon Rectum. 2015;58:1058–1063. doi: 10.1097/DCR.0000000000000452. - DOI - PubMed
    1. Karoui M, Rullier A, Luciani A, Bonnetain F, Auriault ML, Sarran A, Monges G, Trillaud H, Le Malicot K, Leroy K, et al. Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: A multicentre randomised controlled phase II trial-the PRODIGE 22-ECKINOXE trial. BMC Cancer. 2015;15:511. doi: 10.1186/s12885-015-1507-3. - DOI - PMC - PubMed
    1. Nuñez-Sánchez MA, García-Villalba R, Monedero-Saiz T, García-Talavera NV, Gómez-Sánchez MB, Sánchez-Álvarez C, García-Albert AM, Rodríguez-Gil FJ, Ruiz-Marín M, Pastor-Quirante FA, et al. Targeted metabolic profiling of pomegranate polyphenols and urolithins in plasma, urine and colon tissues from colorectal cancer patients. Mol Nutr Food Res. 2014;58:1199–1211. doi: 10.1002/mnfr.201300931. - DOI - PubMed
    1. Kaufman HL, Kim DW, Kim-Schulze S, DeRaffele G, Jagoda MC, Broucek JR, Zloza A. Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory molecules. Hum Gene Ther. 2014;25:452–460. doi: 10.1089/hum.2013.217. - DOI - PMC - PubMed
    1. André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T, Tabernero J, Van Laethem JL, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: Updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol. 2015;33:4176–4187. doi: 10.1200/JCO.2015.63.4238. - DOI - PubMed